Big Pharma's next target? - here's the clue

This patented biotech platform could power 100's of cancer drugs. See who:... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe From our partners at i2i Marketing Group, LLC Big Pharma's Next Target is Already in Play? A small biotech may have cracked one of medicine's biggest problems-how to deliver cancer drugs safely and effectively. Its patented platform could make toxic chemo a thing of the past. With early data drawing Big Pharma's attention, investors are taking notice. Learn which biotech could be next on Big Pharma's acquisition radar

This email communication is a sponsored email for i2i Marketing Group, LLC, a third-party advertiser of MarketBeat. Why did I receive this message?.     We are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company's SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.     If you have questions or concerns about your newsletter, please email our South Dakota based support team at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   Copyright 2006-2025 MarketBeat Media, LLC. All rights protected. 345 N Reid Pl. #620, Sioux Falls, S.D. 57103. U.S.A..